The SPDR S&P Biotech ETF (XBI) experienced a significant outflow of approximately $291 million this week, reflecting a 3.4% decrease in shares outstanding, from 63.9 million to 61.725 million units. This data was reported as of [insert date].
Among the ETF’s largest components, Apellis Pharmaceuticals Inc (APLS) remained flat, while Travere Therapeutics Inc (TVTX) declined by 2.7% and Revolution Medicines Inc (RVMD) increased by 0.7%. The current share price for XBI stands at $135.87, with a 52-week low at $75.68 and a high at $139.19.
For further technical analysis, XBI’s recent trading is also noted in relation to its 200-day moving average.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
